Gilead Sciences (GILD) Non-Current Assets (2009 - 2026)
Gilead Sciences (GILD) posted Non-Current Assets of $37.6 billion for Q1 2026, down 7.48% quarter-over-quarter from $40.7 billion in Q4 2025, and down 4.8% year-on-year from $39.5 billion in Q1 2025.
Gilead Sciences (GILD) Non-Current Assets (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Non-Current Assets for 18 consecutive years, with $37.6 billion the latest figure, recorded in Q1 2026.
- Non-Current Assets for Q1 2026 came in at $37.6 billion, down 4.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $160.0 billion (changed 0.24% YoY), and the FY2025 annual result was $40.7 billion, up 2.16% from the prior year.
- Non-Current Assets was $37.6 billion for Q1 2026 at Gilead Sciences, down from $40.7 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $50.5 billion in Q1 2022 and troughed at $37.6 billion in Q1 2026.
- Average Non-Current Assets over 5 years is $44.1 billion, with a median of $42.3 billion recorded in 2024.
- Year-over-year, Non-Current Assets slipped 14.33% in 2024 and climbed 2.3% in 2025.
- Over 5 years, Non-Current Assets stood at $48.7 billion in 2022, then decreased by 5.52% to $46.0 billion in 2023, then decreased by 13.51% to $39.8 billion in 2024, then gained by 2.16% to $40.7 billion in 2025, then fell by 7.48% to $37.6 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $37.6 billion in Q1 2026, $40.7 billion in Q4 2025, and $40.7 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 61.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 141.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 102.93 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 84.40 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 20.29 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.64 Bn |
| Dec 31, 2025 | 40.68 Bn |
| Sep 30, 2025 | 40.66 Bn |
| Jun 30, 2025 | 41.00 Bn |
| Mar 31, 2025 | 39.53 Bn |
| Dec 31, 2024 | 39.82 Bn |
| Sep 30, 2024 | 39.75 Bn |
| Jun 30, 2024 | 41.26 Bn |
| Mar 31, 2024 | 42.25 Bn |
| Dec 31, 2023 | 46.04 Bn |
| Sep 30, 2023 | 46.39 Bn |
| Jun 30, 2023 | 48.05 Bn |
| Mar 31, 2023 | 48.42 Bn |
| Dec 31, 2022 | 48.73 Bn |
| Sep 30, 2022 | 49.00 Bn |
| Jun 30, 2022 | 49.70 Bn |
| Mar 31, 2022 | 50.45 Bn |
| Dec 31, 2021 | 53.18 Bn |
| Sep 30, 2021 | 53.11 Bn |
| Jun 30, 2021 | 54.06 Bn |